Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research

Acronym

INFRAPLUS

Description of the granted funding

In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine its service portfolio by reducing animal usage and developing alternative cellular models, and optimise the use of resources. INFRAPLUS seeks to achieve several objectives: Developing national node capacities and expertise for providing innovative in vivo, in vitro and preclinical services, developing novel model systems and services to meet the demands of existing and novel user communities, and reducing environmental impact. To achieve these objectives, INFRAPLUS will focus on launching pilot services, refining new technologies, emphasising alternate cellular models, designing and implementing special training programmes and optimising resources for the entire consortium. The project includes a defined service development strategy supported by a strong IT and data management backbone and is built upon the needs of the scientific community. Ultimately, INFRAPLUS will enhance and evolve INFRAFRONTIER's capacity for modelling human diseases and enable breakthrough research by providing researchers cutting-edge tools and services to respond to global biomedical challenges.
Show more

Starting year

2024

End year

2027

Granted funding

243 980 €
Participant
FINNADVANCE OY
72 800 €
Participant
UNITED KINGDOM RESEARCH AND INNOVATION (UK)
187 583 €
Participant
INFRAFRONTIER GMBH (DE)
1 012 256 €
Coordinator
The Hospital for Sick Children (CA)
Participant
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS (EL)
221 800 €
Participant
FUNDACAO CALOUSTE GULBENKIAN (PT)
50 223 €
Participant
BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING (EL)
229 800 €
Participant
USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE (CZ)
274 800 €
Participant
VETERINAERMEDIZINISCHE UNIVERSITAET WIEN (AT)
231 900 €
Participant
KAROLINSKA INSTITUTET (SE)
164 400 €
Participant
CONSIGLIO NAZIONALE DELLE RICERCHE (IT)
244 800 €
Participant
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL)
110 300 €
Participant
UNIVERSITAT AUTONOMA DE BARCELONA (ES)
94 800 €
Participant
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS (ES)
176 534 €
Participant
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE (FR)
290 412 €
Participant
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH (DE)
351 203 €
Participant
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR)
42 300 €
Participant

Amount granted

3 999 891 €

Funder

European Union

Funding instrument

HORIZON Research and Innovation Actions

Framework programme

Horizon Europe (HORIZON)

Call

Programme part
Research infrastructures (11683)
Consolidating and Developing the Landscape of European Research Infrastructures (11684)
Topic
Consolidation of the RI landscape – Individual support for evolution and long-term sustainability of pan-European research infrastructures (HORIZON-INFRA-2023-DEV-01-03)
Call ID
HORIZON-INFRA-2023-DEV-01

Other information

Funding decision number

101131669

Identified topics

bioinformatics